World-Renowned Aging Researcher and Biomedical Gerontologist to Lead
ALAMEDA, Calif. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--
AgeX Therapeutics ("AgeX"), a subsidiary of BioTime, Inc. (NYSE MKT:BTX)
with a focus on developing new therapies in the field of biomedical
gerontology, today announced the appointment of distinguished researcher
and advocate Aubrey de Grey, Ph.D. as Vice-President of New Technology
"One of the world's foremost researchers in the science of aging, and a
tireless advocate for such research, Aubrey will be a strong addition to
AgeX as the Company is positioned to emerge as a leader in the field of
biomedical gerontology," commented Michael D. West, Ph.D., co-CEO of
BioTime. "He has already moved the field forward to a considerable
degree and will help accelerate our research and development programs."
A biomedical gerontologist, Dr. de Grey is Co-Founder and Chief Science
Officer of SENS
Research Foundation, a 501(c)(3) public charity dedicated to
researching, developing and promoting comprehensive regenerative
medicine solutions for the diseases of aging. He will continue in his
current capacity at SENS Research and his role at AgeX will be
part-time. He is also editor-in-chief of the bimonthly academic journal Rejuvenation
Research, from Mary Ann Liebert publishers. He has authored the
books Ending Aging: The Rejuvenation Breakthroughs That Could Reverse
Human Aging in Our Lifetime (co-author, 2008, St. Martin's Griffin)
and The Mitochondrial Free Radical Theory of Aging (1999, R.J
Landes) as well as numerous articles in peer-reviewed scientific
journals. He is a Fellow of the Gerontological
Society of America and the American
Aging Association, and sits on the editorial and scientific advisory
boards of many journals and organizations. He has been interviewed by a
variety of top-tier media outlets, including CBS' "60 Minutes," the New
York Times, FORTUNE, the Washington Post, TIME,
and "The Colbert Report," among many others. He received his B.A. and
Ph.D. from the University of Cambridge, in Cambridge, England.
"The opportunity to help Mike West shape AgeX is a huge next step in my
vision of how to hasten the defeat of aging," said Dr. de Grey. "In
creating a rejuvenation biotechnology industry, it is critically
important to engage new companies and investors in this work. I am
delighted to be involved in the work of a private company like AgeX to
make this happen."
"Attracting Dr. de Grey to AgeX represents a significant milestone in
the company's development and further enhances AgeX's emerging
leadership," stated Adi Mohanty, co-CEO of BioTime. "Additionally, Dr.
de Grey's appointment allows BioTime to better focus on its three core
segments of ophthalmology, aesthetics and cell and drug delivery."
About AgeX Therapeutics
AgeX Therapeutics, a subsidiary of BioTime, Inc. (NYSE MKT:BTX), is a
biotechnology company applying technology relating to cell immortality
and regenerative biology, to aging and age-related diseases. The company
has three initial areas of product development: pluripotent stem
cell-derived brown adipocytes (AGEX-BAT1); vascular progenitors (AGEX-VASC1);
and induced Tissue Regeneration (iTR). Initial planned
indications for these products are Type II diabetes, cardiac ischemia,
and cancer respectively. A discussion with Dr de Grey regarding AgeX can
be viewed here: http://investor.biotimeinc.com/phoenix.zhtml?c=83805&p=irol-EventDetails&EventId=5259612
BioTime is a clinical-stage biotechnology company focused on developing
and commercializing products addressing degenerative diseases. Our
clinical programs are based on two platform technologies: pluripotent
cells and cell/drug delivery. The foundation of our core therapeutic
technology platform is pluripotent cells that are capable of becoming
any of the cell types in the human body. The foundation of our cell
delivery platform is its HyStem® cell and drug delivery matrix
technology. The Company's current clinical programs are targeting three
primary sectors, aesthetics, ophthalmology and cell/drug delivery. We
also have significant equity holdings in two publicly traded companies,
Asterias Biotherapeutics, Inc. ("Asterias") and OncoCyte Corporation
("OncoCyte"), which we founded and which, until recently, were our
majority-owned consolidated subsidiaries.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter,
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
About SENS Research Foundation
SENS Research Foundation is a 501(c)(3) nonprofit that works to
research, develop, and promote comprehensive regenerative medicine
solutions for the diseases of aging. SRF is focused on a damage repair
paradigm for treating the diseases of aging, which it advances through
scientific research, advocacy, and education. SENS Research Foundation
supports research projects at universities and institutes around the
world with the goal of curing such age-related diseases as macular
degeneration, heart disease, cancer, and Alzheimer's disease. Educating
the public and training researchers to support a growing regenerative
medicine field are also major endeavors of the organization that are
being accomplished though advocacy campaigns and educational programs.
For more information, visit www.sens.org.
Certain statements contained in this release are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development, and potential opportunities for BioTime, Inc. and its
subsidiaries, along with other statements about the future expectations,
beliefs, goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical fact
(including, but not limited to statements that contain words such as
"will," "believes," "plans," "anticipates," "expects," "estimates"
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the business of BioTime, Inc. and its
subsidiaries, particularly those mentioned in the cautionary statements
found in more detail in the "Risk Factors" section of its Annual Reports
on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC
(copies of which may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. BioTime specifically disclaims any obligation or
intention to update or revise these forward-looking statements as a
result of changed events or circumstances that occur after the date of
this release, except as required by applicable law.
View source version on businesswire.com:
Source: BioTime, Inc.